Current views on neuropeptide Y and diabetes-related atherosclerosis

Sun, Weiwei; Zhu, Ping; Shi, Yan‐Chuan; Zhang, Chen-liang; Huang, Xu‐Feng; Liang, Shi-yu; Zhang, Song; Lin, Shu

doi:10.1177/1479164117704380

Cited by 26 publications

(15 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, previous data persuasively suggested that the direct effect of NPY on insulin release from isolated islets is inhibitory, while the central effect of NPY indirectly leads to an increase in plasma insulin ( 125 ). The Y1R mediates the inhibitory impact of NPY on insulin secretion on islet β-cells ( 126 ).…”

Section: Npy Indirectly Regulates the Immune Responsementioning

confidence: 99%

Neuropeptide Y Is an Immunomodulatory Factor: Direct and Indirect

Chen

Liu

et al. 2020

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

Neuropeptide Y (NPY), which is widely distributed in the nervous system, is involved in regulating a variety of biological processes, including food intake, energy metabolism, and emotional expression. However, emerging evidence points to NPY also as a critical transmitter between the nervous system and immune system, as well as a mediator produced and released by immune cells. In vivo and in vitro studies based on gene-editing techniques and specific NPY receptor agonists and antagonists have demonstrated that NPY is responsible for multifarious direct modulations on immune cells by acting on NPY receptors. Moreover, via the central or peripheral nervous system, NPY is closely connected to body temperature regulation, obesity development, glucose metabolism, and emotional expression, which are all immunomodulatory factors for the immune system. In this review, we focus on the direct role of NPY in immune cells and particularly discuss its indirect impact on the immune response.

show abstract

Section: Npy Indirectly Regulates the Immune Responsementioning

confidence: 99%

Neuropeptide Y Is an Immunomodulatory Factor: Direct and Indirect

Chen

Liu

et al. 2020

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…NPY receptors are present on distinct populations of sensory neurons, and receptor activation can modulate the activity of nociceptive neurons. Activated NPY receptor inhibits adenylate cyclase through inhibitory G proteins leading to reduced cyclic adenosine monophosphate levels in target cells [ 150 , 151 ].…”

Section: Hypothalamic Neuropeptides In Migrainementioning

confidence: 99%

Targeted Orexin and Hypothalamic Neuropeptides for Migraine

2018

View full text Add to dashboard Cite

The hypothalamus is involved in the regulation of homeostatic mechanisms and migraine-related trigeminal nociception and as such has been hypothesized to play a central role in the migraine syndrome from the earliest stages of the attack. The hypothalamus hosts many key neuropeptide systems that have been postulated to play a role in this pathophysiology. Such neuropeptides include but are not exclusive too orexins, oxytocin, neuropeptide Y, and pituitary adenylate cyclase activating protein, which will be the focus of this review. Each of these peptides has its own unique physiological role and as such many preclinical studies have been conducted targeting these peptide systems with evidence supporting their role in migraine pathophysiology. Preclinical studies have also begun to explore potential therapeutic compounds targeting these systems with some success in all cases. Clinical efficacy of dual orexin receptor antagonists and intranasal oxytocin have been tested; however, both have yet to demonstrate clinical effect. Despite this, there were limitations in these cases and strong arguments can be made for the further development of intranasal oxytocin for migraine prophylaxis. Regarding neuropeptide Y, work has yet to begun in a clinical setting, and clinical trials for pituitary adenylate cyclase activating protein are just beginning to be established with much optimism. Regardless, it is becoming increasingly clear the prominent role that the hypothalamus and its peptide systems have in migraine pathophysiology. Much work is required to better understand this system and the early stages of the attack to develop more targeted and effective therapies aimed at reducing attack susceptibility with the potential to prevent the attack all together.Electronic supplementary materialThe online version of this article (10.1007/s13311-017-0602-3) contains supplementary material, which is available to authorized users.

show abstract

“…Additionally, we cannot draw a causal conclusion that increased NPY serum levels promote MUO development in obese Chinese adults in present study, thus, it may be meaningful and necessary to conduct a prospective research in the future. Finally, it was worth mentioning that NPY exerts biological effects via its receptors and the most well-known being NPY-Y1, NPY-Y2, and NPY-Y5 receptors which are involved in obesity [44,45]. Since these receptors were highly distributed in the hypothalamus and peripheral tissues [44,45], we will detect their serum levels in the future study.…”

Section: Discussionmentioning

confidence: 99%

Higher Serum Neuropeptide Y Levels Are Associated with Metabolically Unhealthy Obesity in Obese Chinese Adults: A Cross-Sectional Study

Tang

Xiao

Chen

et al. 2020

Mediators of Inflammation

View full text Add to dashboard Cite

Objective. Neuropeptide Y (NPY), an orexigenic peptide known to cause hyperphagia, has been involved in the occurrence and development of obesity. However, differences in the distribution of serum NPY levels in obese phenotypes (including metabolically unhealthy obesity (MUO) phenotype and metabolically healthy obesity (MHO) phenotype) and the association of NPY with MUO phenotype have not been unequivocally established. We therefore determined associations of serum NPY levels with MUO phenotype in obese Chinese adults. Methods. A cross-sectional study was conducted from 400 obese adults in Hunan province, who underwent a health examination in the Second Xiangya Hospital, and 164 participants were finally enrolled in the study and divided into MHO and MUO groups. Serum NPY levels were examined; univariate and multivariate analyses as well as smooth curve fitting analyses were conducted to measure the association of NPY serum levels with the MUO phenotype. Results. Serum NPY levels were significantly elevated in the MUO group compared with the MHO group ((667.69±292.90) pg/mL vs. (478.89±145.53) pg/mL, p<0.001). A threshold and nonlinear association between serum NPY levels and MUO was found (p=0.001). When serum NPY levels exceeded the turning point (471.5 pg/mL), each 10 pg/mL increment in the NPY serum level was significantly associated with an 18% increased odds ratio of MUO phenotype (OR: 1.18, 95% CI: 1.07–1.29, p=0.0007) after adjusted for confounders. Conclusions. Higher NPY serum levels were positively correlated with MUO phenotype in obese Chinese adults.

show abstract

Current views on neuropeptide Y and diabetes-related atherosclerosis

Cited by 26 publications

References 91 publications

Neuropeptide Y Is an Immunomodulatory Factor: Direct and Indirect

Neuropeptide Y Is an Immunomodulatory Factor: Direct and Indirect

Targeted Orexin and Hypothalamic Neuropeptides for Migraine

Higher Serum Neuropeptide Y Levels Are Associated with Metabolically Unhealthy Obesity in Obese Chinese Adults: A Cross-Sectional Study

Contact Info

Product

Resources

About